New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus. (PubMed, Diabetes Ther) - Sep 29, 2026 - "These agents hold therapeutic potential in the management of both T2DM and obesity, as shown by preliminary clinical trial outcomes. Further trials are now needed to validate them in clinical practice."
Journal • Review • Anorexia • Diabetes • Fatigue • Genetic Disorders • Metabolic Disorders • Obesity • Pain • Type 2 Diabetes Mellitus
|
|
Djordje S Popovic; Evanthia Gouveri; Nikolaos Papanas; Theodoros Panou
|